Aziz Nakhanov

Prof. Dr. Aziz Nakhanov

Research Institute for Biological Safety Problems, Almaty, Kazakhstan
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
KSKulyaisan Sultankulova
Kulyaisan Sultankulova
GSGaukhar O. Shynybekova
Gaukhar O. Shynybekova
NKNurlan Kozhabergenov
Nurlan Kozhabergenov
NMNazym N. Mukhami
Nazym N. Mukhami
OCOlga Chervyakova
Olga Chervyakova
MOMukhit B. Orynbayev
Mukhit B. Orynbayev
Crimean–Congo hemorrhagic fever (CCHF) disease cases are registered annually in endemic regions of Kazakhstan. To study the prevalence of various Crimean–Congo hemorrhagic fever virus (CCHFV) genotypes, a total of 694 ticks were collected from southern regions of Kazakhstan in 2021. Hyalomma marginatum (n = 323) (46.5%), Hyalomma anatolicum (n = 138) (19.9%), Hyalomma asiaticum (n = 126) (18.2%), Hyalomma scupense (n = 80) (11.5%) and Ixodes ricinus (n = 27) (3.9%) were collected using the standardized flagging technique from the environment. All the tick samples were analyzed for the presence of CCHFV RNA by RT-PCR. The CCHF-positive samples were found within three Hyalomma asiaticum and one Ixodes ricinus tick sample. For the first time in Kazakhstan, infection of the Ixodes ricinus tick with CCHFV was detected. The results of sequencing and analysis of the S-gene fragment showed that the Asia 1 and Asia 2 CCHF genotypes circulate in the southern regions of Kazakhstan. Viruses isolated in the Zhambyl and Turkestan regions are assigned to the Asia-2 genotype, whereas the virus isolated in the Kyzylorda region to the Asia-1 genotype.

25 June 2022 in eClinicalMedicine
Verified
Journal Article
Open access
BKBerik Khairullin
Berik Khairullin
KZKunsulu Zakarya
Kunsulu Zakarya
MOMukhit Orynbayev
Mukhit Orynbayev
YAYergali Abduraimov
Yergali Abduraimov
MKMarkhabat Kassenov
Markhabat Kassenov
LKLespek Kutumbetov
Lespek Kutumbetov
Vaccination remains the primary measure to prevent the spread of the SARS-CoV-2 virus, further necessitating the use of effective licensed vaccines. From Dec 25, 2020, to July 11, 2021, we conducted a multicenter, randomised, single-blind, placebo-controlled phase 3 efficacy trial of the QazCovid-in® vaccine with a 180-day follow-up period in three clinical centres in Kazakhstan. A total of 3000 eligible participants aged 18 years or older were randomly assigned (4:1) to receive two doses of the vaccine (5 μg each, 21 days apart) or placebo administered intramuscularly. QazCovid-in® is a whole-virion formaldehyde-inactivated anti-COVID-19 vaccine, adjuvanted with aluminium hydroxide. The primary endpoint was the incidence of symptomatic cases of the SARS-CoV-2 infection confirmed by RT-PCR starting from day 14 after the first immunisation. The trial was registered with ClinicalTrials.gov NCT04691908. The QazCovid-in® vaccine was safe over the 6-month monitoring period after two intramuscular immunisations inducing only local short-lived adverse events. The concomitant diseases of participants did not affect the vaccine safety. Out of 2400 vaccinated participants, 31 were diagnosed with COVID-19; 43 COVID-19 cases were recorded in 600 placebo participants with onset of 14 days after the first dose within the 180-day observation period. Only one severe COVID-19 case was identified in a vaccine recipient with a comorbid chronic heart failure. The protective efficacy of the QazCovid-in® vaccine reached 82·0% (95% CI 71.1–88.5) within the 180-day observation period. Two immunisations with the inactivated QazCovid-in® vaccine achieved 82·0% (95% CI 71.1–88.5) protective efficacy against COVID-19 within a 180-day follow-up period. The work was funded by the Science Committee of the Ministry of Education and Science of Kazakhstan within the framework of the Scientific and Technical Program “Development of a vaccine against coronavirus infection COVID-19”. State registration number 0.0927.

12 August 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
ANAinur Nurpeisova
Ainur Nurpeisova
BKBerik Khairullin
Berik Khairullin
RARuslan Abitayev
Ruslan Abitayev
KSKamshat Shorayeva
Kamshat Shorayeva
KJKuanysh Jekebekov
Kuanysh Jekebekov
KZKunsulu Zakarya
Kunsulu Zakarya
This article describes the results of a preclinical safety and immunogenicity study of QazCovid-in®, the first COVID-19 vaccine developed in Kazakhstan, on BALB/c mice, rats, ferrets, Syrian hamsters and rhesus macaques (Macaca mulatta). The study’s safety data suggests that this immunobiological preparation can be technically considered a Class 5 nontoxic vaccine. The series of injections that were made did not produce any adverse effect or any change in the general condition of the model animals’ health, while macroscopy and histology studies identified no changes in the internal organs of the BALB/c mice and rats. This study has demonstrated that a double immunization enhances the growth of antibody titers as assessed by the microneutralization assay (MNA) and the enzyme-linked immunosorbent assay (ELISA) in a pre-clinical immunogenicity test on animal models. The best GMT results were assessed in MNA and ELISA 7 days after re-vaccination; however, we noted that GMT antibody results in ELISA were lower than in MNA. A comparative GMT assessment after the first immunization and the re-immunization identified significant differences between model animal groups and a growth of GMT antibodies in all of them; also, differences between the gender groups were statistically significant. Moreover, the most marked MNA immune response to the QazCovid-in® vaccine was seen in the Syrian hamsters, while their SARS-CoV-2-specific antibody activity as assessed with ELISA was the lowest.

26 March 2020 in Microbiology Resource Announcements
Verified
Journal Article
Open access
PDF file
YBYerbol Burashev
Yerbol Burashev
VSVitaliy Strochkov
Vitaliy Strochkov
KSKulyaisan Sultankulova
Kulyaisan Sultankulova
MOMukhit Orynbayev
Mukhit Orynbayev
MKMarkhabat Kassenov
Markhabat Kassenov
KZKunsulu Zakarya
Kunsulu Zakarya
We report the near-complete genome sequence of an influenza H5N1 virus strain isolated from a dead swan on the southeastern Caspian seashore in 2006. The results of the surface protein HA phylogenetic analysis showed that the A/swan/Mangystau/3/2006 virus belongs to the EA-nonGsGD clade.

14 July 2023 in Problems of Particularly Dangerous Infections
Verified
Journal Article
Open access
PDF file
ANAziz Nakhanov
Aziz Nakhanov
KAKh. B. Abeuov
Kh. B. Abeuov
ZOZ. D. Omarova
Z. D. Omarova
TET. T. Ermekbai
T. T. Ermekbai
EBE. D. Burashev
E. D. Burashev
MOMukhit B. Orynbayev
Mukhit B. Orynbayev
In Kazakhstan, foot-and-mouth disease (FMD) outbreaks were recorded in 2011–2013 in the southern and eastern regions where FMD vaccination is in place. In January 2022, in Kiikty village of the Shetsky district, Karaganda Region, Republic of Kazakhstan, cases among cattle clinically similar to foot-and-mouth disease were reported. The aim of the research was to establish the cause of the disease and to perform the typing of the pathogen. Materials and methods. Samples from sick animals were tested using PCR, sequenced and typed in compliance with the protocol developed by the International Office for Epizootic Diseases (OIE). Results and discussion. A cytopathogenic agent has been isolated from the BHK-21 cell culture, identified through real-time RT-PCR and electron microscopically as FMD virus. Molecular genetic studies have revealed that the infection of cattle in the Karaganda Region was caused by the FMD virus circulating in the territory of the countries bordering Kazakhstan (China, Russia, Mongolia) and belonging to type O, topotype ME-SA, genetic line Ind-2001. FMD virus isolated in Kazakhstan is genetically related to the FMD line from Asia and is a new FMDV genotype for Kazakhstan, assigned to the ME-SA topotype of the Ind-2001 genetic line. This study once again proves the need for continuous genetic typing of FMD viruses to improve the effectiveness of preventive measures.

25 June 2020 in Microbiology Resource Announcements
Verified
Journal Article
Open access
PDF file
MOMukhit B. Orynbayev
Mukhit B. Orynbayev
RNR. K. Nissanova
R. K. Nissanova
TATakhmina Argimbayeva
Takhmina Argimbayeva
KZK. D. Zakarya
K. D. Zakarya
BMB. S. Myrzakhmetova
B. S. Myrzakhmetova
KSK. T. Sultankulova
K. T. Sultankulova
We report here the draft genome sequence of the new attenuated strain Neethling-RIBSP of the lumpy skin disease virus, obtained by sequential and alternating passages in cell culture and developing chicken embryos. Genome sequencing allowed the identification of differentiation markers of the new strain.